Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 85
Healthy Volunteers: f
View:

• Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors

• Age between 0 and 85 years

• Availability of sufficient and adequate biological material (tumor tissue and/or blood)

• Signed informed consent for biobanking (BIOTUM)

• Signed informed consent for use of tissue and blood samples in this study

Locations
Other Locations
Italy
Istituto Ortopedico Rizzoli
RECRUITING
Bologna
Contact Information
Primary
Toni Ibrahim, MD Oncologist
toni.ibrahim@ior.it
+39 0516366199
Time Frame
Start Date: 2024-09-23
Estimated Completion Date: 2031-09-23
Participants
Target number of participants: 125
Treatments
Patients with Sarcoma or Bone and Lung Metastases from Solid Tumors
This group includes male and female patients aged 0-85 years diagnosed with sarcomas or with bone or lung metastases from solid tumors and undergoing in surgical removal of the tumor or performing a biopsy. Only patients whose resection will provide sufficient tumor tissue that exceed what is necessary for pathological diagnosis characterization and banking will be enrolled.
Sponsors
Leads: Istituto Ortopedico Rizzoli

This content was sourced from clinicaltrials.gov